$635 Million is the total value of Broadfin Capital, LLC's 45 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 237.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $53,077,000 | +244.0% | 4,146,605 | +354.2% | 8.36% | +247.6% |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $36,604,000 | +34.9% | 1,417,121 | +24.8% | 5.76% | +36.3% |
| CORI | Buy | CORIUM INTL INC | $28,812,000 | -19.5% | 3,597,057 | +15.3% | 4.54% | -18.7% |
| ZGNX | Buy | ZOGENIX INC | $27,509,000 | +27.8% | 622,380 | +15.8% | 4.33% | +29.1% |
| ENDP | New | ENDO INTL PLC | $24,439,000 | – | 2,591,573 | +100.0% | 3.85% | – |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $16,702,000 | -12.7% | 2,724,663 | +3.8% | 2.63% | -11.8% |
| EXAS | New | EXACT SCIENCES CORP | $15,629,000 | – | 261,400 | +100.0% | 2.46% | – |
| ZGNX | New | ZOGENIX INCput | $14,807,000 | – | 335,000 | +100.0% | 2.33% | – |
| ADMA | Buy | ADMA BIOLOGICS INC | $14,657,000 | +342.3% | 3,249,829 | +351.0% | 2.31% | +347.1% |
| TNDM | New | TANDEM DIABETES CARE INC | $12,565,000 | – | 570,598 | +100.0% | 1.98% | – |
| XRAY | New | DENTSPLY SIRONA INC | $11,507,000 | – | 262,900 | +100.0% | 1.81% | – |
| ENDP | New | ENDO INTL PLCcall | $11,316,000 | – | 1,200,000 | +100.0% | 1.78% | – |
| TLGT | Buy | TELIGENT INC NEW | $10,379,000 | +82.7% | 2,999,817 | +77.4% | 1.63% | +84.6% |
| LIVN | New | LIVANOVA PLC | $7,197,000 | – | 72,100 | +100.0% | 1.13% | – |
| MTD | New | METTLER TOLEDO INTERNATIONAL | $6,886,000 | – | 11,900 | +100.0% | 1.08% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $6,236,000 | – | 2,106,589 | +100.0% | 0.98% | – |
| SSKN | Buy | STRATA SKIN SCIENCES INC | $6,035,000 | +2435.7% | 2,943,819 | +1347.7% | 0.95% | +2467.6% |
| TSRO | New | TESARO INCcall | $5,559,000 | – | 125,000 | +100.0% | 0.88% | – |
| XERS | New | XERIS PHARMACEUTICALS INC | $4,745,000 | – | 250,000 | +100.0% | 0.75% | – |
| AMRN | New | AMARIN CORP PLCcall | $4,496,000 | – | 1,455,000 | +100.0% | 0.71% | – |
| HRTX | New | HERON THERAPEUTICS INCcall | $3,885,000 | – | 100,000 | +100.0% | 0.61% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $3,742,000 | – | 1,054,091 | +100.0% | 0.59% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $3,621,000 | – | 80,100 | +100.0% | 0.57% | – |
| QTNT | New | QUOTIENT LTD | $3,531,000 | – | 439,700 | +100.0% | 0.56% | – |
| ATEC | New | ALPHATEC HOLDINGS INC | $3,311,000 | – | 1,111,112 | +100.0% | 0.52% | – |
| ODT | New | ODONATE THERAPEUTICS INC | $2,055,000 | – | 93,081 | +100.0% | 0.32% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INCcall | $352,000 | – | 27,500 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.